Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002275 · ClinicalTrials.gov registry record · NA
A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
A NA study, sponsored by Abbott.
- Completed
- Registry status
- NA
- Development phase
NCT00002275 is a NA study that has completed, run by Abbott.
The verdict
NCT00002275, a NA study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.
Interventions
- DRUG Fat Emulsion 2%
- DRUG Fat Emulsion 20%
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002275
The ClinicalTrials.gov registry entry for NCT00002275 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fat Emulsion 2% is the first listed.
NCT00002275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002275 about?
NCT00002275 is a clinical study titled "A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)". The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic functio...
What is the current status of trial NCT00002275?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002275?
The interventions under investigation include: Fat Emulsion 2% (DRUG), Fat Emulsion 20% (DRUG).
Who is sponsoring clinical trial NCT00002275?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.